Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
Concurrent Nab--paclitaxel/Carboplatin and Thoracic Radiotherapy in Inoperable Stage III Squamous Cell Lung Cancer
Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
Terminated
The study was halted because enrollment was too slow
Other terminated trials from CSPC Ouyi Pharmaceutical Co., Ltd.
More terminations from CSPC Ouyi Pharmaceutical Co., Ltd.
Other Carcinoma, Non-Small-Cell Lung trials with similar outcome
Listed as NCT03802058, this PHASE2 trial focuses on Carcinoma, Non-Small-Cell Lung and Squamous Cell Carcinoma and remains terminated or withdrawn. Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd., it has been updated 8 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2022 — May 2023 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
May 2021 — Jun 2022 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
May 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
Feb 2019 — May 2019 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Wuhan University
For direct contact, visit the study record on ClinicalTrials.gov .